Ayodeji Alaran is the CEO/ founder of PBR Life Sciences, a Life Science Research, Analytics and Advisory Company founded in 2015 with the aim of assisting pharmaceutical companies in maximizing their market potential by providing customized solutions that enhance commercial success and address the prevailing challenges within the industry.
To learn more about PBR’s comprehensive suite of services, feel free to reach out to them via marketanalytics@pbrinsight.com or by using the convenient online contact form on their website.
He holds a bachelor’s degree in Pharmacy from the University of Lagos, along with an MBA from the prestigious London Business School, specializing in various fields such as Strategy, Advanced Marketing Strategy, Managing a Growing Business, Business Analytics, and Private Equity and Venture Capital.
An esteemed member of the Chartered Institute of Marketing UK, Ayodeji Alaran possesses a Professional Diploma from the same institute, as well as a Professional Diploma from the Association of British Pharmaceutical Industry and other certifications. His extensive professional network and experience in building and executing business plans across continents including Africa, Asia, Europe, and North America have been shaped by his working experience at prominent life science companies such as GSK, Johnson & Johnson, Pfizer, AstraZeneca, May & Baker, Cegedim UK, and IQVIA European HQ Organization, among others.
In a publication by THISDAYLIVE this year, Pharm. Ayodeji Alaran shared more insights on “Renaissance: The Size of the Pharmaceutical Opportunities in Nigeria.” He described the pharma industry as a strategic one, providing medication and other sectors the support to strengthen the nation’s security and citizens’ health.
He has also contributed richly to other publications.
Ayodeji Alaran, we appreciate the excellent work and impact you are making in the Life Science Industry in Nigeria.
We celebrate you!
For more insightful content related to the life sciences industry, don’t miss the spotlight on Marvelene Ekott. Read more here.